Drug Profile
Research programme: anti-ischemic therapeutics - Neuronascent
Alternative Names: Anti-ischemic therapeutics - NeuronascentLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Neuronascent
- Class Anti-ischaemics; Small molecules
- Mechanism of Action Cell differentiation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ischaemia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Ischaemia in USA
- 08 Sep 2020 Early research is ongoing in Ischaemia in USA (Neuronascent pipeline, September 2020)
- 13 Oct 2008 Early research in Ischaemia in USA (unspecified route)